A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Study sponsor: Abeona Therapeutics, Inc · ABEO
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-09-30Estimated
Enrollment · participants12Estimated
Source updated2025-06-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.